DOI: https://doi.org/10.21203/rs.3.rs-1734316/v2
Cancer stem cells (CSCs) are a minority population of cancer cells with stemness and multiple differentiation potentials, leading to cancer progression and therapeutic resistance. However, the concrete mechanism of CSCs in hepatocellular carcinoma (HCC) remains obscure. We found that in advanced HCC tissues, collagen Ⅰ was upregulated, which is consistent with the expression of its receptor DDR1. Accordingly, high collagen Ⅰ levels accompanied by high DDR1 expression are associated with a poor prognosis in patients with HCC. Collagen Ⅰ-induced DDR1 activation enhanced HCC cell stemness in vitro and in vivo. Mechanistically, DDR1 interacts with CD44, which acts as a co-receptor that amplifies collagen Ⅰ-induced DDR1 signaling, and collagen Ⅰ-DDR1 signaling antagonized Hippo signaling by facilitating the recruitment of PP2AA to MST1, leading to exaggerated YAP activation. The combined inhibition of DDR1 and YAP synergistically abrogated HCC cell stemness in vitro and tumorigenesis in vivo. A radiomic model based on T2 weighted image can noninvasively predict collagen Ⅰ expression. These findings reveal the molecular basis of collagen Ⅰ-DDR1 signaling inhibiting Hippo signaling and highlight the role of CD44/DDR1/YAP axis in promoting cancer cell stemness, suggesting that DDR1 and YAP may serve as novel prognostic biomarkers and therapeutic targets in HCC.
Hepatocellular carcinoma (HCC) is one of the most prevalent causes of cancer-related mortality worldwide 1. High tumor recurrence and metastasis rates are the primary reasons for the high mortality rate associated with HCC 2. Chronic hepatitis, fibrosis, and cirrhosis increase the risk of HCC. The intratumor of HCC is constantly accompanied by desmoplasia and cirrhosis 3–4. Inflammation and extracellular matrix (ECM) deposition are characteristics of cirrhosis and the tumor microenvironment (TME). ECM serves as a physical scaffold that binds cells and tissues together and is pivotally involved in biochemical and biophysical signal transduction. Matrix deposition and remodeling cause tumor stiffness. Increased stiffness activates biomechanical signaling pathways that promote proliferation, invasiveness, and metastasis of cancer cells 5. Recent studies have demonstrated that the ECM, especially collagen, contributes to immune exclusion in tumors with collagen-rich stroma 6–8. Collagens are the primary and essential components of the ECM, an integral component mechanics, and are hot off the press in cancer microenvironment research 9. Collagens resist tensile stress because they stiffen as they are stretched in response to store growth-induced anxiety. Intratumor stress significantly decreases after collagen digestion 10.
High matrix stiffness induces and enhances the stemness of HCC cells 11. Cancer stem cells (CSCs) are a group of cancer cells with stemness properties that possess self-renewal and differentiation capacities, leading to tumor progression, therapy resistance, metastasis, and recurrence 12–13. Increased ECM stiffness can be a physical barrier that protects CSCs from chemotherapeutic agents and CD8+ T cell killing 14. Changes in biomechanical properties, such as intrinsic softness, may be unique markers of CSCs 15.
In addition to the effects of external mechanics, the maintenance effect of collagen on tumor stem cells remains unclear. Collagen regulates cell function through its corresponding receptor discoidin domain receptor 1 (DDR1) 16. DDR1 belongs to the receptor tyrosine kinase (RTKs) family and is mainly expressed in epithelial cells and mammalian tissues. Its specific ligands are natural collagen I~Ⅵ 17. Our previous study showed that DDR1 enhanced hepatocellular carcinoma metastasis by recruiting PSD4 to ARF6 18 and promoted HCC proliferation through the mTORC1 signaling pathway 19. However, the role and precise mechanism of DDR1 in maintaining hepatocellular carcinoma stemness remain unclear.
Numerous upstream signals direct YAP/TAZ activity, including mechanical forces, cell adhesion, cell polarity, tyrosine kinase receptors, and cellular metabolism 20–21. Upon Hippo signaling off, nuclear YAP/TAZ are translocated from the cytoplasm, combined with the TEA domain transcription factor family (TEAD 1–4 22) directing gene expression programs 23–24. Based on the YAP-on and YAP-off classifications, restraining YAP may be an attractive therapeutic strategy for HCC, defined as the YAP-on stage 25. YAP/TAZ are essential for cancer cells to reprogram into cancer stem cells and induce tumor initiation, progression, and metastasis 26. However, the mechanism by which Hippo signaling affects HCC stemness has not yet been elucidated.
As one of the upstream receptors, CD44 is a broadly distributed non-kinase transmembrane glycoprotein that belongs to the cell adhesion molecule (CAMs) family, and is involved in cell physiological and pathological processes 27–28. Recent studies aim at the new function that CD44 acted as a co-receptor that mediated multiple RTKs inducing intracellular signal transduction 29–30. As an RTK family member, we speculated that DDR1 may be modified by CD44.
A preoperative and non-invasive method for evaluating collagen content is vital for surgeons because of the role of collagen I in HCC. Radiomics is an emerging imaging technique that can extract high-throughput imaging features from medical images and is frequently applied to predict the biological behavior of various tumors31–32. Using radiomics signatures, we constructed a model for predicting collagen I expression in HCC.
This study showed that DDR1 stimulated by collagen I inhibited the Hippo pathway in HCC cells to maintain stemness through YAP nuclear translocation. Specifically, collagen I-induced DDR1 stimulation was augmented by the co-receptor CD44. DDR1 recruits PP2AA for MST1/2 dephosphorylation upon collagen I stimulation, thereby activating YAP translocation. Therefore, we identified a direct association between collagen I -DDR1 signaling and Hippo-YAP signaling in promoting HCC cells stemness. Furthermore, our studies indicate that inhibiting DDR1 signaling combined with disrupting YAP function could be a novel treatment method for HCC. A radiomics model based on T2-weighted images (T2WI) can evaluate relative collagen I expression to predict the prognosis and guide clinical treatment.
High collagen I and DDR1 level predicts poor prognosis in HCC patients.
To analyze the types of collagens in the intratumor of HCC, we performed Picro-Sirius red staining in HCC tissues. The results showed that collagen I occupied the highest proportion of type Ⅰ~Ⅳ collagens (Fig. 1A). To explore the clinical significance of collagen I in HCC, we tested collagen I expression in a tissue microarray including 123 HCC tissue samples with corresponding clinicopathological features from Tongji Hospital (Supplementary Table S1). Compared with well-differentiated HCC tissues, collagen I was mainly highly expressed in moderately differentiated HCC tissues and was highest in poorly differentiated tissues (Fig. 1B). Kaplan–Meier analysis demonstrated that patients with high collagen I expression in tumors had a lower overall survival rate and a higher recurrence rate than patients with low collagen I expression (Fig. 1C). Tumor sphere-forming assays showed the ability of collagen I in promoting HCC cell stemness (Fig. 1D). Among the collagen I-specific receptors 33, silencing DDR1 significantly reduced the Hep3B and HLF cells stemness induced by collagen I (Supplementary S1A).
To examine the clinical significance of DDR1 in HCC, we analyzed the levels of DDR1 in the same tissue microarray and TCGA databases. The results showed that DDR1 positively correlated with collagen I (Fig. 1E–F, Supplementary S1B). Based on collagen I and DDR1 expression, patients were sorted into three groups: Col1+DDR1+(n = 54), double-high expression of collagen I/DDR1; Col1+DDR1−or Col1−DDR1+ (n = 33), single-high expression of collagen I or DDR1; Col1−DDR1− (n = 36), double-low expression of collagen I/DDR1. Compared to the other groups, the Col1+DDR1+ group showed the shortest overall survival time and disease-free survival time (Fig. 1G). In addition, DDR1 expression was elevated in HCC tissues compared to those in the corresponding adjacent non-tumor tissues. DDR1 was highly expressed in advanced TNM stages, poor tumor differentiation, advanced BCLC stage, and cirrhosis (Supplementary S1C–E, Supplementary Table S2). Kaplan–Meier analysis demonstrated that patients with high DDR1 expression had a lower overall survival rate and a higher recurrence rate (Supplementary S1F). In summary, the relationship between collagen I and DDR1 in clinical samples suggested that the synergistic impact of collagen I and DDR1 yielded a poor clinical outcome in HCC patients and they might play an essential role in the occurrence and development of HCC.
Collagen I-DDR1 signaling enhances characteristics of cancer stemness.
To verify the effect of DDR1 on HCC cell stemness in vitro, we performed sphere-forming assays. We found that the protein level of DDR1 was strongly upregulated in HCC spheres (referred to as CSCs) compared to the corresponding cultured adherent cells (referred to as non-CSCs) (Fig. 2A). As crucial transcription factors and membrane proteins in maintaining the self-renewal potential of stem cells 34, overexpression of DDR1 promoted mRNA expression of SOX2, NANOG, and EPCAM. Collagen I stimulation further amplified this effect. However, overexpression of the DDR1 kinase-dead (DDR1-K618A) and collagen-binding-defective (DDR1-R105A) mutants did not achieve this effect. In contrast, DDR1 knock-down diminished the expression of the former mRNA (Supplementary S2A). From TCGA database, DDR1 expression was positively correlated with CD133, which was verified by IHC of the tissue microarray (Fig. 2B–C). Furthermore, DDR1 overexpression or collagen I stimulation induced prominent promotion of sphere formation efficiency, number of CD133 positive cells, single-cell colony formation, and drug resistance to sorafenib or doxorubicin. In contrast, overexpression of DDR1-K618A and DDR1-R105A mutants failed to show the same results. In comparison, DDR1 depletion significantly reduced these CSC-related biological effects (Fig. 2D–G, Supplementary S2B–E).
In vivo, We used a xenograft model to examine the role of DDR1 in HCC cells. The subcutaneous tumors formed by DDR1 knock-down sphere-formed cells were significantly smaller than those formed by scramble cells (Fig. 3A). IHC results showed that the protein levels of DDR1, Ki67, and CD133 were higher in scrambled tumors than in DDR1 knock-down tumors (Fig. 3B). To further examine the role of DDR1 in tumor tumorigenesis, we injected NOD/SCID mice subcutaneously, with or without up-regulated DDR1 cells to conduct a limiting dilution assay. DDR1 overexpression markedly strengthened the tumor-forming ability and increased stem cell frequency (Fig. 3C–E). Together, the aforementioned confirmed that DDR1 promotes cell stemness and tumorigenesis in HCC in vitro and vivo, depending on its kinase activity and collagen stimulation.
Collagen-induced DDR1 activation is synergistically promoted by CD44.
To investigate the molecular mechanism of DDR1 in hepatocellular carcinoma, we studied its interacting partners using a combined IP/MS approach. SK-Hep1 cells were transfected with FLAG-DDR1 or FLAG-vector, and immunoprecipitated using anti-FLAG antibody. We found that CD44 (a CSCs marker) was one of the potential interacting partners of DDR1 (Fig. 4A)18. Co-immunoprecipitation (Co-IP) and glutathione S-transferase (GST) pull-down assays were performed, and the results from endogenous and exogenous assays showed that DDR1 interacted and combined with CD44 (Fig. 4B–C). In addition, the spatial co-localization of exogenous DDR1 and CD44 in 293T cells was detected by immunofluorescence and laser confocal scanning. A similar finding was observed for endogenous DDR1 and CD44 in the HLF cells (Fig. 4D). At the mRNA and protein levels, regulation was not observed between CD44 and DDR1 in Q-PCR and western blot assays (Supplementary S3.A–D). Next, we performed a co-IP assay with or without collagen I activation and found that collagen I increased the interaction between DDR1 and CD44 (Fig. 4E). As CD44 can act as a co-receptor to mediate receptor internalization, activation, degradation, or regulation of receptor kinase activity 35–37, we speculated whether CD44 could regulate collagen I-induced DDR1 activation. Co-IP assays indicated that CD44 knock-down decreased tyrosine phosphorylation of DDR1 (Fig. 4F). Overexpression of CD44 promoted the phosphorylation of DDR1 induced by collagen I treatment in a time-dependent manner. Knock-down of DDR1 reduced this effect in the HLF cells (Fig. 4G). Our results suggest that CD44 promotes the collagen I-induced activation of DDR1 in HCC cells. Whether the function of CD44 in HCC depends on DDR1 or not, we knocked down DDR1 in CD44-overexpressing HLF cells and overexpressed DDR1 in CD44 knock-down Hep3B cells. DDR1 depletion partially diminished the HCC cells in sphere formation efficiency, single-cell colony formation, CD133 positive stem-like-cell proportion, and chemoresistance driven by CD44 overexpression. Overexpression of DDR1 partially enhanced CSCs characteristics that were reduced by CD44 depletion within collagen I (Fig. 5A–D). The volume and weight of subcutaneous tumors developed by CD44 overexpression cells were significantly greater than those generated by the vector or CD44/shDDR1 cells (Fig. 5E). In summary, the above evidence suggests that DDR1 is a crucial protein required for CD44-mediated HCC cell stemness signaling.
DDR1 inactivates Hippo signaling by facilitating the recruitment of PP2AA to MST1/2
To identify the pathways responsible for the influence of DDR1 on HCC cell stemness, we performed RNA sequencing of DDR1 knock-down HCC cells and control cells. KEGG pathway analysis revealed that Hippo signaling was significantly altered by DDR1 loss (Fig. 6A, Supplementary Table S3). Based on TCGA database, DDR1 was positively associated with YAP, CTGF, BCL2, and AXL (Supplementary S4A–D). Hippo signaling is closely associated with tumor stemness, we examined the effects of DDR1 on the expression of genes downstream of YAP/TAZ (Hippo pathway core proteins). The results showed that the mRNA levels of CTGF, CYR61, BCL2, and AXL were upregulated after the overexpression of DDR1 in Hep3B cells. The presence of collagen I further enhances these effects. In contrast, DDR1 knock-down significantly reduced the expression of CTGF, CYR61, BCL2, and AXL (Fig. 6B). The dual-luciferase reporter system suggested that DDR1 enhanced the YAP/TEAD-responsive element activity within collagen I (Fig. 6C). Nuclei-cytoplasmic fractionation and immunofluorescence assay indicated that DDR1 overexpression promoted the translocation of YAP into the nucleus (Fig. 6D–E). Western blotting showed that collagen I-stimulated DDR1 phosphorylation reduced MST1 phosphorylation and enhanced YAP activation, whereas DDR1 knock-down showed the opposite effect (Fig. 6F). These results indicated that collagen I-DDR1 signaling induces YAP activation.
protein phosphatase 2 scaffold subunit A alpha (PP2AA; PPP2R1A) as a canonical upstream phosphatase could dephosphorylate MST1/2 and inactivate Hippo signaling 35–37. We analyzed DDR1 interacting partners. PP2AA is a potential interacting protein with of DDR1 (Fig. 4A). Recruiting assays demonstrated that DDR1 promoted the recruitment of PP2AA to MST1 in a collagen-dependent manner (Fig. 6G). PP2AA depletion attenuated collagen I-DDR1 signaling-induced MST1 and LAST1 dephosphorylation, leading to YAP activation (Fig. 6H). These results indicated that PP2AA is necessary for collagen I -DDR1 signaling induced YAP activation.
In clinical samples, we evaluated p-DDR1, CD44, and YAP protein levels in 39 tissue samples from patients with HCC undergoing surgery at our hospital. The results showed that p-DDR1, CD44, and YAP levels were positively correlated in HCC tissues (Fig. 6I). Based on the IHC staining of collagen I, the samples were separated into collagen I-positive (collagen I +) and collagen I-negative (collagen I -) expression groups. We then performed multicolor immunofluorescence (IF) analyses to analyze the co-localization of these three proteins (Fig. 6J). As described above, p-DDR1 and CD44 levels were strongly correlated with YAP expression during collagen I deposition.
Combined inhibition of DDR1 and YAP induces synergistic effects in HCC cell stemness.
To verify whether DDR1 functions via YAP, we used in vitro and in vivo treatments with the DDR1 inhibitor (7rh) 39 and the YAP inhibitor (verteporfin; VP) 40. 7rh is an ATP-competitive oral DDR1-specific small-molecule inhibitor41. Verteporfin (VP), an inhibitor of YAP/TAZ, was identified in a small library of FDA-approved compounds and has been reported to sterically hinder the interaction between YAP and TEAD 42. Treatment with 7rh or VP alone reduced the number of cells with sphere formation efficiency, colony formation, and CD133 + cell proportion and reduced the volume and weight of xenografts, respectively. Combination treatment with 7rh and VP further attenuated these effects compared to single agents (Fig. 7A–D). IHC results showed that Ki67 and CD133 staining was more intense in scrambled tumors than in 7rh or VP treatment tumors. The combination group yielded the lowest Ki67 and CD133 expression in tumors (Fig. 7E), and the combined treatment showed a favorable effect on anti-tumor therapy.
Clinical-radiomics predictive model
Among the patients in the tissue microarray, we acquired 92 T2WI images, and a total of 65 patients were finally included in this retrospective study. The prediction model depends on the collagen I IHC score. Patients were divided into high and low groups. Model performance was evaluated using receiver operating characteristic (ROC) curve analysis. The results showed that the model based on 14 features obtained the highest AUC for the validation data set (Fig. 8A). At this point. The AUC and prediction accuracy of the model were 0.717 and 0.700, respectively, for the testing data-set. The clinical statistics for diagnosis and selected features are shown (Fig. 8B).
Dysregulation of the matricellular components of the tumor microenvironment has been linked to the development of metastases in multiple cancer types. The ECM is a non-cellular three-dimensional macromolecular network composed of collagens, elastin, laminins, fibronectin, proteoglycans, and other glycoproteins 43. The exact mechanism of ECM in tumors has not yet been elucidated. In the present study, we aimed to identify the crucial components—collagen and its receptor DDR1. We found that the phosphorylation of DDR1 by collagen contributes to the maintenance of HCC cell stemness. In an attempt to identify collagen Ⅰ-DDR1 crucial for regulating CSCs, we found collagen Ⅰ-DDR1 signaling antagonized Hippo signaling with the help of CD44 amplification. The combination of DDR1 and YAP inhibition is a logical target for anti-cancer stem cell-directed therapies, and a radiomic predictive model for collagen Ⅰ can distinguish between chemotherapeutic efficacy and predicted prognosis. In recurrent HCC, mRNA and protein levels of DDR1 are higher in recurrent HCC than those in non-recurrent HCC 44. High DDR1 expression is associated with advanced tumor stages 45. Similar to the observations in our study, patients with DDR1 high expression had worse OS and DFS rates with accompanying collagen Ⅰ deposition.
As a well-accepted theoretical model, cancer stem cells give rise to chemoresistance, metastasis, and recurrence in tumors. The CSCs model has been verified in various solid tumors, including HCC 46. Extracellular matrix (ECM) rigidity segregates CSCs from chemotherapeutic agents as a physical defender and plays a critical role in tumor progression, especially in cancer cell stemness 14. ECM stiffness contributes to NANOG activation and cancer stemness 47.
Extensive studies have demonstrated that ECM and collagens can cross-talk with cancer cells, including cancer stem cells, to promote tumor progression 48–49. Rich collagens in airway smooth muscle cells contribute to tumor cell colonization in the lung (55) and participate in cancer stemness, progression, and treatment 4,50−52. The above studies revealed that collagens could act as ligands that cross-talk with collagen receptors in the surrounding tumor cells 53 and that DDR1-dependent collagen remodeling contributes to immune exclusion in breast cancer 8. This evidence suggests that CSCs tend to be enriched in stiffer microenvironment which warrants further in-depth studies. Our study demonstrated that through the corresponding receptor - DDR1, exogenous collagen I enhanced HCC cell stemness. Higher collagen I expression was positively correlated with DDR1 expression in clinical samples with poor prognosis. We demonstrated that collagen I - DDR1 signaling contributes to the maintenance of HCC stemness and progression.
DDR1, an RTKs, is upregulated in multiple cancers 54–55. We demonstrated that DDR1 mediates regulatory mechanisms involved in the maintenance of HCC cell stemness. Functionally, DDR1 is dependent on collagen I stimulation and its kinase activity. It interacts with CD44, which amplifies collagen I-induced DDR1 phosphorylation signaling, CD44/DDR1/YAP signaling axis acts as an inducer of the stemness of HCC cells by DDR1 activation. The results have not determined other components of the ECM that enhance collagen Ⅰ-induced DDR1 activation, and the role of different types of collagens in HCC stemness deserves further study.
CD44 promotes migration, invasion, and tumor progression by interacting with various proteins. Nevertheless, the regulatory relationship between CD44 and Hippo signaling is not directly precise 56–57. Rho A, merlin, and PI3K/Akt have been implicated in CD44-Hippo signaling 58–60. A previous study demonstrated that CD44 acts as a ligand-binding membrane protein and co-receptor that mediates ligand-receptor-induced intracellular signal transduction 35. In this study, CD44 was found to function as a co-receptor of DDR1 by negotiating and magnifying collagen I-DDR1 phosphorylation. Our research revealed a new interaction and was complementary to the analysis of the relationship between CD44 and Hippo signaling pathway.
Hippo signaling is an evolutionarily conserved pathway consisting of a network of signals to modulate tissue growth and organ size, and dysregulation of Hippo signaling contributes to human cancer progression 40,61−62. Recent study indicated that DDR1 can sense the increasing matrix stiffness through control YAP/TAZ activity 63. Our results further confirmed that collagen I - DDR1 signaling maintained HCC cell stemness by inhibiting Hippo signaling. STRIPAK integrates upstream signals to regulate the activities of MST1/2 and MAP4Ks, leading to the initiation of Hippo signaling 38. We found that DDR1 acts as an adaptor protein that recruits PP2AA to MST1. Our study is the first discovered collagen I - DDR1 signaling suppress Hippo signaling in maintaining HCC cell stemness.
Moreover, the DDR1 inhibitor − 7rh unveiled a significant treatment effect on pancreatic ductal adenocarcinoma and KRAS-mutant lung adenocarcinoma 64–66. Originally, verteporfin was in clinical use as a photosensitizer in photocoagulation therapy for macular degeneration, and now it shows potential anti-cancer and anti-antifibrotic treatment in clinical trials and basic experiments 67–70. The combination of 7rh and VP therapy had synergistic effects on reducing HCC cell stemness. In addition, VP decreased CD44 levels, and this positive feedback loop may be inactivated by disrupting DDR1 phosphorylation. These findings provide a theoretical basis and present novel therapeutic targets for HCC progression.
Since collagen I content estimates matter in the prognosis of inhibitor treatment, we can rely on radiomics to provide a non-invasive evaluation method for collagen I expression and needle biopsy. Radiomics applied within clinical-decision support systems to improve diagnostic, prognostic, and predictive accuracy is gaining importance in cancer research 71. In this retrospective study, we constructed and validated T2WI radiomic signatures for the preoperative prediction of collagen I expression status in HCC. The radiomic model could predict collagen I expression and confirm its predictive value, which could be used to stratify patients into groups based on collagen I levels to guide treatment. This approach might allow clinicians to select more personalized and effective treatment strategies, as it demands more imaging samples and practice in the future.
In summary, our results illustrate that collagen I-DDR1 signaling magnified by CD44 acts as a tumor motivator to promote HCC cell stemness by recruiting PP2AA to activate YAP. In HCC tissues, increased collagen I and DDR1 expression predicts poor prognosis and thus can serve as promising biomarkers and novel therapeutic strategies for HCC.
HLF, Hep3B, SK-Hep1, and HEK293T cells were cultured in high-glucose Dulbecco’s modified Eagle’s medium (DMEM, HyClone, Illinois, USA) supplemented with 10% fetal bovine serum (FBS, Gibco, New York, USA), 100 U/ml penicillin and 100 mg/ml streptomycin (HyClone, Illinois, USA) at 37°C with 5% CO2. Collagen1 treatment was administered at a final concentration of 20 µg/ml. All the cell lines were obtained from the Hepatic Surgery Center, Tongji Hospital, Huazhong University of Science and Technology, China. 293 T cells were purchased from the China Center for Type Culture Collection (Wuhan, China).
To calculate sphere-forming efficiency, cells were single-cell sorted into 96-well plates coated with an ultra-low attachment surface (Corning). The cells were grown under anchoring-independent conditions in selective serum-free DMEM/F12 medium supplemented with 1X B27 supplement minus vitamin A (LifeTechnologies), human recombinant EGF (hEGF) (R&D System) (20 ng/mL), and bFGF (R&D system) (20 ng/mL). After seven days, the spheres formed were counted.
Cells were suspended and seeded at a density of 1000 cells per well. After three weeks of cultivation, the cells were fixed and stained with 10% formalin and 0.1% crystal violet. The relative number of colonies was counted.
Cells were stained with a PE-conjugated CD133 (BD Biosciences) antibody in PBS with 2% FBS at 4°C for 30–60 mins. Isotype-matched mouse immunoglobulins were used as the controls. The samples were analyzed using the CytoFLEX flow cytometer and CytExpert software (Beckman Coulter).
Cells in the logarithmic growth phase were uniformly inoculated into 96-well plates (1000/well) and different diluted drug concentrations were added to the medium. Six replicate wells were used for each concentration gradient assay. The cells were cultured in an incubator for 48 h. Subsequently, 10 µL of CCK-8 solution (Vazyme, Nanjing, China) and 90 µL of culture medium were added, followed by incubation in the dark at 37°C for 1 h. Absorbance at 450 nm was detected using GraphPad Prism (Version 8, GraphPad Software, San Diego, CA).
Transient small interfering RNA (siRNA) assays were described before 72. Sequences of siRNA are listed in Supplementary Table S4. Synthesizing siRNA duplexes were produced and validated by Ribobio (Guangzhou, China). Human DDR1 (NM_001954.4) cDNA and pcDNA3.1, plasmids were gifts from the Hepatic Surgery Center, Tongji Hospital, Huazhong University of Science and Technology, China. pBABE-puro (plasmid #1764), gag/pol (plasmid #14887), pMD2.G(plasmid #12259), pLKO.1 - TRC cloning vector (plasmid #10878), and psPAX2 (plasmid #12260) were purchased from Addgene (Cambridge, MA, USA). To establish pBABE- FLAG- DDR1, human cDNA was cloned into the BamHI/EcoRI site of the pBABE-puro retroviral vector and identified via sequencing (TSINGKE, Wuhan, China). To construct pLKO.1-scramble, pLKO.1-shDDR1, and pLKO.1- shCD44 plasmid, the target double-stranded oligonucleotides (shRNA) sequences, and one non-targeting sequence (negative control, scramble) were annealed and cloned into the AgeI/EcoRI site of the pLKO.1 vector. The shRNA oligo-pair sequences are listed in Supplementary Table S4. Viral production, infection, and establishment of stable cell clones have been described previously 73. The pcDNA3.1 plasmid inserted by FlAG- or HA-tagged DDR1 and its mutants, FlAG- or HA-tagged CD44, FlAG-tagged PP2AA were constructed according to the ClonExpress II One Step Cloning Kit and Mut Express II Fast Mutagenesis Kit V2 (Vazyme, Nanjing, China) protocol and were identified by sequencing (TSINGKE, Wuhan, China). The CD44-overexpressing lentivirus was purchased from DesignGene Biotechnology (Shanghai, China)
293 T cells transiently transfected with FLAG-DDR1 or FLAG-vector were lysed in IP lysis buffer (25mM Tris-HCl (pH 7.4), 150mM NaCl, 1% NP-40, 1mM EDTA, 10% glycerol, and protease inhibitor cocktail), and IP assays were performed as described previously 18. The eluted proteins were separated by SDS-PAGE followed by coomassie blue staining. There was a significant difference in the gel bands between the FLAG-DDR1 and FLAG-vector groups among the molecular weight 70kd-125kd regions. Mass spectrometry was performed and analyzed using the ptm-bio lab (PTM BIO, Hangzhou, China).
Total cell RNA was extracted using TRIzol (Invitrogen, Carlsbad, CA, USA). Reverse transcription was carried out using HiScript II Q Select RT SuperMix (+ gDNA wiper) (Vazyme, Nanjing, China) according to the manufacturer’s instructions. Real-time fluorescence quantitative PCR was performed using the ChamQ Universal SYBR qPCR Master Mix (Vazyme, Nanjing, China). Gene expression levels were normalized to those of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) in the same samples. Each sample was analyzed independently in triplicate. The primers used are listed in Supplementary Table S5.
Immunoblotting and co-immunoprecipitation assays were performed as previously described 18. Briefly, cells were collected and lysed on ice using IP lysis buffer. Lysates were incubated with protein G agarose for 2 h and immunoprecipitated with indicated antibodies overnight at 4°C. The lysates were incubated with protein G agarose beads for 1 h followed by 1wash using IP lysis buffer and three washes with washing buffer (300mM NaCl, 1.0mM EDTA, 25mM Tris-HCl, pH7.4, 1.0% NP-40). The beads were eluted with 2×SDS-PAGE loading buffer and subjected to immunoblotting.
The human DDR1 gene encoding was subcloned into a pET-42b vector. Following transformation and amplification in BL21(DE3) E. coli, recombinant GST-DDR1 fusion proteins were purified by GST Purification MagBeads (Absin Bioscience, Shanghai, China). GST (5 µg) or GST-DDR1 (5 µg) was incubated with recombinant human His-CD44 protein (5 µg) (ABclonal Technology, Wuhan, China) in PBS at 4°C for 4 h under constant mixing. The bound proteins were incubated and immunoprecipitated with GST antibody-protein A beads (Absin Bioscience, Shanghai, China). After washing away the unbound proteins three times, the bound proteins were analyzed by SDS-PAGE and immunoblotting.
Immunofluorescence assays were performed as described previously 72. Briefly, after the indicated treatments, cells were cultured on coverslips for 12 h, fixed in 4% paraformaldehyde for 15 min at room temperature, and permeabilized with 0.5% Triton X-100 for 10 min. After blocking, slides were incubated with primary antibody overnight at 4°C in a humidified box. The slides were then washed thrice and incubated with secondary antibody for 4 h at room temperature in a humidified box. Finally, the cell nuclei were stained with 40, 60-diamidino-2-phenylindole (DAPI, Sigma-Aldrich) for 5 min. The resulting signals were visualized using a confocal laser scanning microscope (Olympus FV1000, Tokyo, Japan).
Cells were seeded in a 24-well plate at a density of 10000 cells per well. The next day, cells were co-transfected with 200ng pGL4.17 and 4ng pRL-TK plasmids, and transfections were performed using Lipofectamine 3000 (Thermo Fisher Scientific, Waltham, MA, United States) according to the manufacturer's instructions. 12 h after transfection, cells were replaced with fresh medium and allowed to grow for 48 h. Luciferase activity was detected with the Dual-Luciferase Reporter Assay System (Promega, Madison, WI, United States) using a GloMax 20/20 Luminometer (Promega, Madison, WI, United States). Firefly luciferase activity was normalized to the Renilla luciferase activity.
Rattail collagen I (BD Bioscience, MA, USA), Puromycin, trypsin-EDTA, Opti-MEM, and polybrene were obtained as previously described 19. DDR1 inhibitor 7rh, and YAP inhibitor verteporfin were purchased from MedChemExpress (Shanghai, China). The Lipofectamine 3000 reagent was purchased from Invitrogen (Life Technologies, Carlsbad, CA, USA). All the antibodies used in this study are listed in Supplementary Table S6.
Thirty-six male NOD/SCID mice (4 weeks old) were divided into two groups (18 mice per group): a group receiving SK-Hep1 cells with vector and a group receiving cells overexpressing DDR1.The cells were diluted and transplanted by subcutaneous injection. Tumors were harvested at the end of the experiment for documentation. Tumor-initiating cell frequency was calculated using the extreme limiting dilution analysis (ELDA) software 74. Animal assays were carried out according to Wuhan Medical Experimental Animal Care Guidelines.
Cells (2 × 106) were subcutaneously injected into 4-week-old nude mice. After 2 weeks, the animals were orally administered verteporfin (50 mg/kg) and 7rh (50 mg/kg) twice daily for two weeks. Drugs delivered by oral gavage were dissolved in DMSO and diluted in corn oil. Control mice were treated with the vehicle following an identical procedure. Mice were killed (within 48 h of the last treatment), and samples were obtained for histopathological and immunohistochemical analysis.
From February 1, 2014 to December 31, 2015, 123 human tissues were authorized by the Hepatic Surgery Center, Tongji Hospital, Huazhong University of Science and Technology (Wuhan, China). All the participants provided written informed consent. Patients who had received radiotherapy or chemotherapy before surgery were excluded. Survival time was calculated from the date of surgery to the date of death or last follow-up. Tumor staging was performed according to the Seventh edition of the Tumor-Node-Metastasis (TNM) Classification of the International Union Against Cancer 75. HCC samples (n = 123) were used to generate a tissue microarray (Shanghai Biochip Co., Ltd. Shanghai, China). The fundamental processes of the Immunohistochemistry assay have been previously mentioned 18. The pathological types of paraffin-embedded slides were rechecked by HE staining before IHC analysis. A DAB substrate kit (Zsbio Commerce Store) was used according to the manufacturer’s instructions. Scores for staining frequency (0 < 10%, 1 = 10–25%, 2 = 26–50%, 3 = 51–75%, 4 = > 75%) and intensity (0 = negative, 1 = weak, 2 = moderate, 3 = intense staining) were used. A DAB substrate kit (Zsbio Commerce Store) was used according to the manufacturer’s instructions. The overall staining score (OSS) was calculated by multiplying the staining area percentage score by the intensity score. 0–6 were considered low, and 9–12 were considered high. The results were scored by two pathologists who were blinded to clinicopathological data. All procedures were approved by the Ethics Committee of Tongji Hospital and conducted according to the Declaration of Helsinki Principles. Written and informed consent was obtained from each patient.
Cells were lysed using TRIzol reagent (Invitrogen, Life Technologies, Carlsbad, CA, USA). RNA extraction, library construction, high-throughput sequencing, and data analysis were conducted by Novogene Technology Co., Ltd. (Beijing, China).
65 patients were retrospectively recruited between February 1, 2014 and December 31, 2015. We randomly selected 45 cases as the training data set (25/20 = positive/negative) and another 20 cases as the independent testing data set (11/9 = positive/negative). Two independent readers manually delineated all MR images as high-resolution T2-weighted images (T2WI) using an open-source software package (ITK-SNAP, version 3.6.0, www.itksnap.org). Tumors were outlined as regions of interest (ROIs). Two types of images, “original images” and “wavelet images,” were used for the analysis in this study. “Original images” were the images without any transformation, and “wavelet images” were used for image denoising and improving image quality. The original images underwent a three-dimensional (i.e., x, y, and z directions) wavelet transformation using the PyWavelet package in Python. Each image was filtered by a high bandpass filter or low band-pass in the three directions, resulting in 8 combinations of different decompositions: LLH, LHL, HLL, LHH, HHL, HLH, HHH, and LLL (H means high, and L means low). The FeAture Explorer Pro (FAE Pro, V 0.4.1) was used to extract radiomic features. The shape features were extracted only from the “original images.” 18 types of first-order statistical features, 14 types of shape features, and 75 types of texture features [24 Gray Level Co-occurrence Matrix (GLCM) + 14 Gray Level Dependence Matrix (GLDM) + 16 Gray Level Run Length Matrix (GLRLM) + 16 Gray Level Size Zone Matrix (GLSZM) + 5 Neighborhood Gray-tone-difference Matrix (NGTDM)], a total of 107 “original images” features were used for analysis in our study. “Wavelet images” contained 144 first-order statistical features [8 wavelet images × 18] and 600 texture features [8 wavelet images × 75]. All 851 characteristics were extracted from the visible primary tumors, recorded, and stored quantitatively (Supplementary Table S7).
To remove the imbalance in the training data set, we used the synthetic minority oversampling technique (SMOTE) to balance the positive/negative samples. Normalization was applied to the feature matrix. Each feature vector was subtracted from the mean value of the vector and divided by its length. Because the dimension of the feature space was high, we compared the similarity of each feature pair. If the PCC value of the feature pair was greater than 0.99, one of them was removed. After this process, the feature space dimension was reduced, and each feature was independent. Before building the model, we used analysis of variance (ANOVA) to select features. The F-value was calculated to evaluate the relationship between the features and labels. We sorted the features according to their corresponding F-values and assigned a specific number of features to build the model. We used a support vector machine (SVM) as the classifier. The kernel function can map the features into a higher dimension to search the hyper-plane to separate cases with different labels. To determine the hyper-parameter of the model (e.g., the number of features), we applied a cross-validation 5-fold on the training data set. The hyper-parameters were selected according to model performance on the validation data-set. The model performance was evaluated using receiver operating characteristic (ROC) curve analysis. The area under the ROC curve (AUC) was calculated for quantification. Acuracy, sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) were also calculated at a cutoff value that maximized the value of the Yorden index. We also estimated the 95% confidence interval using bootstrapping with 1000 samples. The above processes were implemented using the FeAture Explorer Pro (FAEPro, V 0.4.1) on Python (3.7.6).
Statistical analyses were performed using GraphPad Prism (Version 8, GraphPad Software, San Diego, CA). The levels of statistical significance for comparing the two groups were evaluated using the non-parametric two-sided Mann–Whitney U-test. To compare several groups with a control group, one-way ANOVA followed by Dunnett’s multiple comparison test was applied. Two-way ANOVA followed by Bonferroni post-test was applied to compare several groups with a control group over time. Statistical significance was set at P < 0.05. Survival curves were generated using the Kaplan–Meier procedure. Survival curves and hazard ratios were evaluated using log-rank tests.
DDR1, discoidin domain receptor 1; HCC, hepatocellular carcinoma; GGT, γ-Glutamyl transpeptidase; Q-PCR, quantitative real-time PCR; Co-IP, co-immunoprecipitation; GST, glutathione S-transferase; WB, western blot; IHC, immunohistochemistry; IF, immunofluorescence.; CTGF, connective tissue growth factor; CYR61, cysteine rich angiogenic inducer 61; BCL2, BCL2 apoptosis regulator; AXL, AXL receptor tyrosine kinase; PP2AA, protein phosphatase 2 scaffold subunit A alpha.
Acknowledgements
We thank all study subjects for their participation in this study.
Declaration of competing interest
The authors declare that they have no conflict of interest.
Authors’ contributions
WGZ contributed to the conception. XCZ and WGZ contributed to the study design. HFL and ZGZ form the overarching research goals and aims. YXX and XCZ wrote the main manuscript text. YXX, JHZ, YXZ and YLP contributed to the acquisition, analysis, and interpretation of the data. WGZ supervised the research activity planning. JJL and YXL verified the results/experiments and other research outputs. WGZ support the finance of the project. YW and JPZ critically revised the manuscript. All authors read and approve the final manuscript.
Ethics approval and consent to participate
All procedures were approved by the Ethics Committee of Tongji Hospital and conducted according to the Declaration of Helsinki Principles. Written and informed consent was obtained from each patient.
Funding
This study was supported by the National Natural Science Foundation of China (No. 81874149 to Wanguang Zhang; No. 82103606 to Xiaochao Zhang).
Data Access Statement
Research data supporting this publication are available from the StarBase website 76.